Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Papillary Lesions of the Breast at Percutaneous Core-Needle Biopsy1

Papillary Lesions of the Breast at Percutaneous Core-Needle Biopsy1 Purpose: To retrospectively review the imaging and histologic findings in patients in whom a benign papillary lesion was diagnosed at core-needle breast biopsy. Materials and Methods: This retrospective study was approved by the institutional review board at each institution; patient consent was not required. The study was HIPAA compliant. The authors reviewed the findings from 42 patients (age range, 26–76 years; mean age, 54.3 years) with 43 benign papillary lesions diagnosed at core-needle biopsy. Thirty-six (84%) of the 43 lesions were surgically excised, and seven (16%) were followed up with long-term imaging. The authors assessed the radiographic findings, the histologic findings at core-needle biopsy, and the findings at subsequent surgical excision or imaging follow-up. Statistical analysis was performed on a per-patient basis and included the Blyth-Still-Casella procedure to construct exact 95% confidence intervals (CIs) and the Fisher exact test. Results: At core-needle biopsy, lesions were diagnosed as papilloma ( n = 29), sclerosing papilloma ( n = 8), and benign papillary lesions not otherwise specified ( n = 6). For the 36 lesions that were surgically excised, histologic follow-up showed no residual lesion in 10, intraductal papilloma in 14, intraductal papillomatosis in two, papilloma with adjacent foci of atypical ductal hyperplasia (ADH) in eight, and well-differentiated papillary ductal carcinoma in situ (DCIS) in two. Mammographic follow-up in the remaining seven lesions revealed stable calcifications in five (at 28–55 months) and no residual lesion in two (at 26–29 months). In nine of the 42 patients (21%), the diagnosis was upgraded to either ADH or DCIS (exact two-sided 95% CI = 11.4%, 36.4%). Conclusion: The results strongly suggest that papillary lesions diagnosed as benign at core-needle biopsy should be surgically excised because a substantial number of lesions were upgraded to ADH and DCIS at excision. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Radiology Radiological Society of North America, Inc.

Papillary Lesions of the Breast at Percutaneous Core-Needle Biopsy1

Loading next page...
 
/lp/radiological-society-of-north-america-inc/papillary-lesions-of-the-breast-at-percutaneous-core-needle-biopsy1-rEqSzH3FQW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Radiological Society of North America, Inc.
Copyright
Copyright © 2006 by Radiological Society of North America
ISSN
1527-1315
eISSN
0033-8419
DOI
10.1148/radiol.2382041839
pmid
16424237
Publisher site
See Article on Publisher Site

Abstract

Purpose: To retrospectively review the imaging and histologic findings in patients in whom a benign papillary lesion was diagnosed at core-needle breast biopsy. Materials and Methods: This retrospective study was approved by the institutional review board at each institution; patient consent was not required. The study was HIPAA compliant. The authors reviewed the findings from 42 patients (age range, 26–76 years; mean age, 54.3 years) with 43 benign papillary lesions diagnosed at core-needle biopsy. Thirty-six (84%) of the 43 lesions were surgically excised, and seven (16%) were followed up with long-term imaging. The authors assessed the radiographic findings, the histologic findings at core-needle biopsy, and the findings at subsequent surgical excision or imaging follow-up. Statistical analysis was performed on a per-patient basis and included the Blyth-Still-Casella procedure to construct exact 95% confidence intervals (CIs) and the Fisher exact test. Results: At core-needle biopsy, lesions were diagnosed as papilloma ( n = 29), sclerosing papilloma ( n = 8), and benign papillary lesions not otherwise specified ( n = 6). For the 36 lesions that were surgically excised, histologic follow-up showed no residual lesion in 10, intraductal papilloma in 14, intraductal papillomatosis in two, papilloma with adjacent foci of atypical ductal hyperplasia (ADH) in eight, and well-differentiated papillary ductal carcinoma in situ (DCIS) in two. Mammographic follow-up in the remaining seven lesions revealed stable calcifications in five (at 28–55 months) and no residual lesion in two (at 26–29 months). In nine of the 42 patients (21%), the diagnosis was upgraded to either ADH or DCIS (exact two-sided 95% CI = 11.4%, 36.4%). Conclusion: The results strongly suggest that papillary lesions diagnosed as benign at core-needle biopsy should be surgically excised because a substantial number of lesions were upgraded to ADH and DCIS at excision.

Journal

RadiologyRadiological Society of North America, Inc.

Published: Mar 1, 2006

There are no references for this article.